# RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

> **NCT06495307** · PHASE1,PHASE2 · TERMINATED · sponsor: **Lubris Bio Pty Ltd** · enrollment: 3 (actual)

## Conditions studied

- Ocular Graft-versus-host Disease

## Interventions

- **DRUG:** rhPRG4

## Key facts

- **NCT ID:** NCT06495307
- **Lead sponsor:** Lubris Bio Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-02-14
- **Primary completion:** 2025-03-22
- **Final completion:** 2025-03-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Efficacy signal substantial enough to more to larger study
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06495307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06495307, "RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06495307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*